Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2015157409) MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2015/157409 International Application No.: PCT/US2015/024909
Publication Date: 15.10.2015 International Filing Date: 08.04.2015
IPC:
A61K 31/282 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
28
Compounds containing heavy metals
282
Platinum compounds
Applicants:
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US/US]; Boyd Graduate Studies Research Center Athens, Georgia 30602-7411, US
Inventors:
DHAR, Shanta; US
PATHAK, Rakesh; US
MARRACHE, Sean; US
Agent:
CAMPBELL, Keith; US
Priority Data:
61/976,55908.04.2014US
PCT/US2014/06999712.12.2014US
PCT/US2015/01872004.03.2015US
Title (EN) MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG
(FR) PROMÉDICAMENT À BASE DE PLATINE (IV) CIBLANT LES MITOCHONDRIES
Abstract:
(EN) Pt(IV) compounds include a mitochondria targeting moiety. One example of a Pt(IV) compound having a mitochondria targeting moiety is a Pt(IV) cisplatin-based compound. Upon reduction, the mitochondrial targeting moieties are released resulting in a Pt(II) therapeutic agent. Pt(IV) compounds including a mitochondria targeting moiety can be included in nanoparticles. The compounds or nanoparticles can be used to treat, for example, cancer.
(FR) Les composés à base de Pt(IV) comprennent une fraction de ciblage des mitochondries. Un exemple d'un composé à base de Pt(IV) ayant une fraction de ciblage des mitochondries est un composé à base de Pt(IV) cisplatine. Lors de la réduction, les fractions de ciblage des mitochondries sont libérées, résultant en un agent thérapeutique Pt(II). Les composés à base de Pt(IV) comprenant une fraction de ciblage des mitochondries peuvent être inclus dans des nanoparticules. Les composés ou nanoparticules peuvent être utilisés pour traiter, par exemple, le cancer.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)